# gnpc
**Global Neurodegeneration Proteomics Consortium**

Visit **neuroproteome.org**
or scan QR code to learn more
in neuro-proteome
X @_neuroproteome
✉ info@neuroproteome.org

# Can we accelerate drug discovery and diagnostic development for millions of dementia patients by measuring 300,000,000 proteins across multiple neurodegenerative diseases?

**The Global Neurodegeneration Proteomics Consortium (GNPC)** has brought together top dementia researchers from around the world to collaborate on proteomic and associated clinical data analysis to transform patient trajectories and improve quality of life.

**The GNPC v1 Harmonized Dataset is now available on the AD Discovery Portal, enabling large-scale proteomic data sharing at scale.**

~35,000 proteomic samples fully anonymized and over 50 clinical features focusing on:

- Healthy aging
- Alzheimer's disease (AD)
- Parkinson's disease (PD)
- Amyotrophic lateral sclerosis (ALS)
- Frontotemporal dementia (FTD)

**Scan to read the series of 6 articles on the GNPC published with Nature family journals**

**Apply here to access the v1 Harmonized Data Set on the AD Workbench**

## GNPC Research Aims & Goals

**Unite proteomics data across neurodegeneration cohorts**
To bring together diverse data and top dementia researchers to collaborate on **the largest protein biomarker discovery effort to date**

**Establish a framework for data sharing**
To leverage secure cloud-based data sharing structures and **solve cross-cohort data harmonization headaches** via a generalizable model for data contribution and secure harmonization

**Attract future cohorts**
To provide **rapid, mutual access to shared data** and promote dataset growth by encouraging **straightforward addition of future diverse cohorts.**

## What's Next? GNPC vMultiplatform (vMP) Expansion Priorities

**Multiple proteomic data platforms**
SomaScan 11k, Olink HT, Alamar Biosciences (NULISA CNS & Inflammation)

**Greater geographic diversity**
**Expanding the participating cohorts** with studies based in Africa, Latin America, East Asia, and South Asia

**Inclusion of interventional cohorts**
Growing beyond observational data by bringing in studies with behavioral and lifestyle modification as well as pharmacological interventions (e.g. anti-amyloid therapies)

**New data informatics partners**
Integration **of new automated data analysis pipelines** (low-code/no-code) via GRIP, digital twin modeling, and **novel AI/ML model development**

**New funding partners**
GNPC vMP is made possible with support from **philanthropic and industry partners**, including Gates Ventures, Janssen Research & Development LLC, a Johnson & Johnson company, ADDF's DxA, GSK plc., the Robertson Foundation, Sanofi, and the Shanahan Foundation.

## HDS Version Life Cycle

**Data Contribution and Harmonization**

Contributor data is harmonized and anonymized into a single Harmonized Dataset.

The consortium utilizes workspaces on the AD Workbench to securely share and harmonize the data.

**Embargo Period**

GNPC Consortium members receive 12 months of early access to the HDS to report on summary findings.

**Public Release**

After one year of intra-consortium analysis, the HDS is released to the research community as a shared global resource for approved use and users.

The **v1 HDS** is now available on request via the AD Workbench.

The **vMP** will be available Summer 2027